Related Experiment Video
Updated: Aug 15, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes
Michael L Christensen1, Bernd Meibohm, Edmund V Capparelli
1University of Tennessee, 50 North Dunlap, Room 306, Memphis, TN 38103, USA.
Abstract:
This study assessed the single- and multiple-dose pharmacokinetics of 3 doses (15 mg, 30 mg, and 45 mg) of pioglitazone in 36 adolescents with type 2 diabetes. Blood samples were obtained over a 48-hour interval after the first dose (day 1) and over a 72-hour interval after the last dose (day 15) of pioglitazone and were assayed for pioglitazone and active metabolites (M-III and M-IV). Pioglitazone systemic exposure increased dose dependently but was less than dose proportional during multiple dosing. The median peak pioglitazone concentration occurred at 2 hours. The mean half-life was 8 to 9 hours for pioglitazone and 24 to 32 hours for M-III and M-IV, with similar values at each dose level. During multiple dosing, accumulation for pioglitazone was negligible, but it reached 2.5- to 3.0-fold for M-III and M-IV. The sustained total serum concentration of active compounds during multiple dosing provides the basis for once-daily dose administration of pioglitazone in adolescents.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Oral Hypoglycemic Agents: Biguanides and Glitazones
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Bioavailability Study Design: Single Versus Multiple Dose Studies
Oral Hypoglycemic Agents: Glinides